



This is a repository copy of *Cognitive impairment in adults with epilepsy: The relationship between subjective and objective assessments of cognition*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/90641/>

Version: Accepted Version

---

**Article:**

Samarasekera, S.R., Helmstaedter, C. and Reuber, M. (2015) Cognitive impairment in adults with epilepsy: The relationship between subjective and objective assessments of cognition. *Epilepsy and Behavior*, 52 (Part A). 9 - 13. ISSN 1525-5050

<https://doi.org/10.1016/j.yebeh.2015.08.013>

---

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

|                      | <b>RHH<br/>(n=39)</b> | <b>UHCW<br/>(n=43)</b> | p-value | Mean % |
|----------------------|-----------------------|------------------------|---------|--------|
| Age (Years)*         | 41.0 (18 – 76)        | 39.0 (19 – 81)         | 0.632   |        |
| Gender               |                       |                        |         |        |
| Male                 | 16 (41.0%)            | 22 (51.2%)             | 0.384   | 46.1   |
| Female               | 23 (59.0%)            | 21 (48.8%)             |         | 53.9   |
| Epilepsy Type        |                       |                        |         |        |
| Structural/metabolic | 29 (74.3%)            | 34 (79.1%)             | 0.914   | 76.7   |
| Genetic generalised  | 8 (20.5%)             | 7 (16.3%)              |         | 18.4   |
| Unspecified          | 2                     | 2                      |         |        |
| Seizure Frequency    |                       |                        |         |        |
| >1/day               | 3 (7.7%)              | 3 (7.0%)               | 0.741   | 7.35   |
| >1/week              | 5 (12.8%)             | 6 (14.0%)              |         | 13.4   |
| >1/month             | 16 (41.1%)            | 12 (27.9%)             |         | 34.5   |
| >1/year              | 10 (25.6%)            | 13 (30.2%)             |         | 27.9   |
| ≤1/year              | 5 (12.8%)             | 9 (20.9%)              |         | 16.9   |
| AED Therapy          |                       |                        |         |        |
| Monotherapy          | 15 (38.5%)            | 17 (40.4%)             | 1       | 39.5   |
| Polytherapy          | 24 (61.5%)            | 25 (59.5%)             |         | 60.5   |
| No AEDs              | 0                     | 1                      |         |        |

table 1. Demographic and Clinical characteristics of study population  
p-values from Fisher's Exact Test unless stated otherwise

\*Data displayed as: Median (Range); p-value from Mann-Whitney Test

| ABNAS domain       | Patients | Carers | p-value* |
|--------------------|----------|--------|----------|
| Fatigue            | 50       | 45     | 0.527    |
| Slowing            | 47       | 53     | 0.424    |
| Memory             | 55       | 38     | 0.011    |
| Concentration      | 43       | 43     | 1        |
| Motor coordination | 24       | 40     | 0.016    |
| Language           | 39       | 39     | 1        |

table 2 . Number of patients with moderate/serious symptoms in each of the ABNAS domains, as reported by both patients and carers.

\* p-values from Fisher's Exact Test unless stated otherwise

Epitrack score

|         | Cognitive impairment            | No cognitive impairment         |
|---------|---------------------------------|---------------------------------|
|         | n=59                            | n=23                            |
| ABNAS   | High: 50 (85%)<br>Low: 9 (15%)  | High:16 (70%)<br>Low: 7 (30%)   |
| C-ABNAS | High: 43 (73%)<br>Low: 16 (27%) | High: 13 (57%)<br>Low: 10 (43%) |

table 3. Concordance between objective (Epitrack) and subjective (ABNAS/C-ABNAS) assessment measures.




fig 1a. Relative proportion of patients experiencing significant cognitive impairment as stratified by the number of AEDs prescribed.




fig 1b. Relative proportion of patients experiencing significant cognitive impairment as stratified by their antiepileptic drug risk score.




fig 2a. The relative contribution of factors predicting cognition as assessed by the Epitrack score.




fig 2b. The relative contribution of factors predicting cognition as assessed by the ABNAS score.




fig 2c. The relative contribution of factors predicting cognition as assessed by the C-ABNAS score.